Role of autophagy-related protein in the prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgical resection

Perng, Daw‐Shyong; Hung, Chao‐Ming; Lin, Hung‐Yu; Morgan, Paul; Hsu, Yao-Chun; Wu, Tsung‐Chin; Hsieh, Pei‐Min; Yeh, Jen‐Hao; Hsiao, Po‐Jen; Lee, Chih-Yuan; Li, Yuchan; Wang, Ya-Chin; Chen, Yaw‐Sen; Lin, Chih‐Wen

doi:10.1186/s12885-021-08553-6

Cited by 6 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For patients with tumors of combined HCC and CCA (cHCC-CC), microtubule-associated protein 1A/1B-light chain 3 (LC3) increased tissue expression was found to predict postresection OS (5-year OS, 61.2%) and disease-free survival (74.6%)[ 70 ].…”

Section: Proteinsmentioning

confidence: 99%

Novel approaches in search for biomarkers of cholangiocarcinoma

Mocan¹,

Ilieș²,

Melincovici³

et al. 2022

WJG

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) arises from the ductular epithelium of the biliary tree, either within the liver (intrahepatic CCA) or more commonly from the extrahepatic bile ducts (extrahepatic CCA). This disease has a poor prognosis and a growing worldwide prevalence. The poor outcomes of CCA are partially explained by the fact that a final diagnosis is challenging, especially the differential diagnosis between hepatocellular carcinoma and intrahepatic CCA, or distal CCA and pancreatic head adenocarcinoma. Most patients present with an advanced disease, unresectable disease, and there is a lack in non-surgical therapeutic modalities. Not least, there is an acute lack of prognostic biomarkers which further complicates disease management. Therefore, there is a dire need to find alternative diagnostic and follow-up pathways that can lead to an accurate result, either singlehandedly or combined with other methods. In the "-omics" era, this goal can be attained by various means, as it has been successfully demonstrated in other primary tumors. Numerous variants can reach a biomarker status ranging from circulating nucleic acids to proteins, metabolites, extracellular vesicles, and ultimately circulating tumor cells. However, given the relatively heterogeneous data, extracting clinical meaning from the inconsequential noise might become a tall task. The current review aims to navigate the nascent waters of the non-invasive approach to CCA and provide an evidence-based input to aid clinical decisions and provide grounds for future research.

show abstract

Section: Proteinsmentioning

confidence: 99%

Novel approaches in search for biomarkers of cholangiocarcinoma

Mocan¹,

Ilieș²,

Melincovici³

et al. 2022

WJG

View full text Add to dashboard Cite

show abstract

“…In the light of these observations, it has been hypothesized that Immunoexpression of p62/SQSTM1/Sequestosome-1 in human primary and recurrent IDH1/2 wild-type glioblastoma: A pilot study p62 may promote the progression of cancer by repressing the apoptotic resistance and generating reactive oxygen species (ROS), thus, enhancing cell proliferation, tumorigenesis, and metastasis (20)(21)(22)(23).…”

Section: Introductionmentioning

confidence: 99%

“…Some reports have documented an evident p62 expression in pancreatic, hepatocellular, mammary, and oral squamous carcinomas, in which aggressive clinicopathological features and poor prognosis have been referred ( 16 – 20 ). In the light of these observations, it has been hypothesized that p62 may promote the progression of cancer by repressing the apoptotic resistance and generating reactive oxygen species (ROS), thus, enhancing cell proliferation, tumorigenesis, and metastasis ( 20 – 23 ).…”

Section: Introductionmentioning

confidence: 99%

Immunoexpression of p62/SQSTM1/Sequestosome‑1 in human primary and recurrent IDH1/2 wild‑type glioblastoma: A pilot study

et al. 2022

View full text Add to dashboard Cite

Asbstract. p62/SQSTM1/Sequestosome-1 is an autophagic protein that serves a crucial role in cellular metabolism, proliferation and malignant growth. Notably, autophagy may influence the development and resistance to therapy of numerous types of human cancer. In the present pilot study, the immunohistochemical pattern of p62 was analyzed in a cohort of patients with isocitrate dehydrogenase (IDH)1/2 wild-type glioblastoma (GBM), in primary and recurrent samples, in order to verify the concordance or discordance between the primary and recurrent tumors. In addition, the association between p62, and patient outcome and O 6 -methylguanine-DNA methyltransferase (MGMT) status was assessed. The results revealed p62 immunoexpression in the nucleus and cytoplasm of neoplastic elements in 45% of primary and 55% of recurrent cases of GBM. A discordant p62 immunoreactivity was detected in 35% of cases, with a variation either with positive or negative conversion of p62 status. Statistically, p62 expression and MGMT status exhibited a significant prognostic value by univariate analysis, whereas only MGMT promoter methylation status emerged as an independent prognostic factor by multivariate analysis. Finally, the most favorable prognosis was documented when the same GBM case was positively concordant for both p62 expression and MGMT methylated status. Since little data are available regarding the association between p62 expression and MGMT in GBM, further investigations may be required to determine if new targeted therapies may be addressed against autophagy-related proteins, such as p62.

show abstract